Free tool
FAERS Monitor: Retrovir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019951 or its brand name (Retrovir, Zidovudine). Reports on generic versions are filed under their own applications.
Reports
13,354
Serious
12,637
95% of reports
Hospitalization
3,356
Death reported
1,659
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy2,183
- drug exposure during pregnancy1,074
- anaemia937
- virologic failure816
- drug resistance732
- premature baby731
- exposure during pregnancy663
- pathogen resistance599
- viral mutation identified568
- maternal exposure during pregnancy523
- pyrexia471
- lipodystrophy acquired436
- pain427
- treatment failure423
- death418
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 544 |
| 2005 | 542 |
| 2006 | 791 |
| 2007 | 608 |
| 2008 | 579 |
| 2009 | 630 |
| 2010 | 597 |
| 2011 | 465 |
| 2012 | 423 |
| 2013 | 408 |
| 2014 | 457 |
| 2015 | 697 |
| 2016 | 1,264 |
| 2017 | 987 |
| 2018 | 834 |
| 2019 | 722 |
| 2020 | 908 |
| 2021 | 541 |
| 2022 | 460 |
| 2023 | 398 |
| 2024 | 193 |
| 2025 | 148 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lipodystrophy acquiredSignal | 436 | 406.7 | 366.6 | 139,949 |
| viral mutation identifiedSignal | 568 | 286.9 | 262.8 | 136,694 |
| virologic failureSignal | 816 | 281.5 | 261.8 | 193,327 |
| pathogen resistanceSignal | 599 | 110.7 | 102.1 | 60,771 |
| drug exposure during pregnancySignal | 1,074 | 51.3 | 48.4 | 51,366 |
| drug resistanceSignal | 732 | 46.2 | 43.0 | 31,421 |
| foetal exposure during pregnancySignal | 2,183 | 43.4 | 41.8 | 88,380 |
| premature babySignal | 731 | 39.2 | 36.5 | 26,539 |
| exposure during pregnancySignal | 663 | 17.0 | 15.8 | 9,872 |
| maternal exposure during pregnancySignal | 523 | 9.3 | 8.5 | 3,855 |
| treatment failureSignal | 423 | 8.1 | 7.4 | 2,613 |
| anaemiaSignal | 937 | 7.8 | 7.3 | 5,545 |
| pyrexiaSignal | 471 | 2.1 | 2.0 | 291 |
| pain | 427 | 1.1 | 1.0 | 4 |
| death | 418 | 0.8 | 0.7 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.